Volodymyr D. Babadzhan

Volodymyr D. Babadzhan

Auto-generated profile, based on publicly available information

Volodymyr D. Babadzhan

Kharkiv National Medical University, Nauky ave., 4, Kharkiv, 61022

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2018 in Klinicheskaia khirurgiia
Verified
Journal Article
Open access
PDF file
DMD. V. Minukhina
D. V. Minukhina
VBV. D. Babadzhan
V. D. Babadzhan
VBV. V. Boyko
V. V. Boyko
VMV. V. Minukhin
V. V. Minukhin
DYDenys Oleksandrovych Yevtushenko
Denys Oleksandrovych Yevtushenko
Objective. To estimate the levels of inhibitor of the plasminogen activator type 1 (ІPA-1) and аsymmetrical dimetilarginin (АDMА) in patients with an acute myocardial infarction (AMI), depending on presence or absence of diabetes mellitus type II (DM2) and character of the coronary arteries (CA) affection, аs well as their prognostic significance concerning degree of the coronary vessels atherosclerotic changes. Маterials and methods. There were examined 130 patients, 44 (33,85%) - women and 86 (66.15%) - men. All the patients were distributed into two groups: the main - 73 patients with AMI and concurrent DM2, among which there were 43 men and 30 women, average ageing (62.73 ± 1.39) yrs old, and a comparative one - 57 patients with AMI without DM2, including 43 men and 14 women, average ageing (63.98 ± 1.47) yrs old. Control group consisted of 20 practically healthy persons (including 10 men and 10 women, average ageing (60.85 ± 1.37) yrs old). In all the patients a coronarography in standard projections was conducted, using angiograph Siemens Axiom Artis. The ADMA content was established, using immunoassay method, with the help of a commercially available test-system «Immunodiagnostik», manufactured by the ADMA Xpress ELISA Kit (Аustria) company, ІPA-1 - by immunoassay method as well, using a commercially available test-system, manufactured by Technoclone PAI-1 ELISA Kit (Аustria) firm. Results. In the patients, suffering AMI, not depending on the DM2 presence or absence, the ІPА-1 та АDМА levels are raised, comparing with a control group (р < 0.05). In the patients, suffering hemodynamically significant stenosis (HSS) of CА (70% and more) there were registered the raised levels of ІPA-1 and АDМА while the DM2 presence or absence (р < 0.05). In the patients, suffering an AMI and diffuse affection (DA) of CА, with concurrent DM2 or without it, the levels of ІPA-1 and АDMA were trustworthily higher, than in the patients without DA of CA (р < 0.05). Conclusion. Comparison of squares under the ROC-curves have shown, that IPA-1 has more diagnostic significance for prognostication of DA of CA in patients with an AMI and concurrent DM2, than АDМА. It is expedient to determine the levels of ІPA-1 and АDМА for prognostication of HSS of CA and diagnosis of the coronary bed DA with the objective to prevent the development of the AMI complications.

23 December 2025 in Pathologia
Verified
Journal Article
Open access
KBK. M. Borovyk
K. M. Borovyk
OKO. I. Kadykova
O. I. Kadykova
PKP. H. Kravchun
P. H. Kravchun
VBV. D. Babadzhan
V. D. Babadzhan
NRN. H. Ryndina
N. H. Ryndina
ASA. O. Sypalo
A. O. Sypalo
The aim: to evaluate serum nesfatin-1 levels and their correlation with lipid profile parameters in patients with ischemic heart failure (HF) with and without concomitant metabolic comorbidities such as type 2 diabetes mellitus (T2DM) and obesity. Materials and methods. The study included 225 patients with HF due to ischemic heart disease, divided into four groups: Group 1 (n = 75) – with T2DM and obesity; Group 2 (n = 50) – with T2DM; Group 3 (n = 50) – with obesity; Group 4 (n = 50) – without metabolic disturbances. Serum nesfatin-1 levels were determined using an enzyme-linked immunosorbent assay (ELISA). Biochemical analysis included measurements of total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and very-low-density lipoprotein cholesterol (VLDL-C), as well as calculation of the atherogenic coefficient (AC). Correlation analysis was performed using Spearman’s rank correlation test. Results. In patient groups with concomitant metabolic comorbidities (Groups 1, 2, and 3), statistically significant inverse correlations were observed between serum nesfatin-1 levels and pro-atherogenic lipids (TC, TG, LDL-C, VLDL-C), along with a significant direct correlation with the anti-atherogenic fraction (HDL-C). In these groups, higher nesfatin-1 levels were associated with a significant decrease in TC (17.6–24.6 %), TG (11.3–49.6 %), LDL-C (29.1–65.0 %), and AC (49.7–59.6 %), alongside an increase in HDL-C (23.1–44.7 %). In contrast, in Group 4 (patients without metabolic disturbances), the effect of nesfatin-1 on the lipid profile was less pronounced. While TG levels decreased significantly (by 28.6 %), other parameters (TC, HDL-C, LDL-C, AC) showed no statistically significant changes or only minimal variations. These findings suggest a context-dependent role of nesfatin-1 in lipid metabolism, with more pronounced effects in the presence of metabolic comorbidities. Conclusions. Elevated serum nesfatin-1 levels are associated with an improved lipid profile in patients with ischemic HF complicated by type 2 diabetes mellitus and/or obesity, suggesting a potential protective role of this peptide in the presence of metabolic comorbidities. In contrast, in patients without metabolic disturbances, this effect is markedly attenuated or absent. These findings underscore the need for further investigation into the underlying mechanisms of nesfatin-1 action across different clinical populations.

22 November 2023 in Clinical and Preventive Medicine
Verified
Journal Article
Open access
PDF file
KBKateryna M. Borovyk
Kateryna M. Borovyk
NRNataliia G. Ryndina
Nataliia G. Ryndina
OKOlga I. Kadykova
Olga I. Kadykova
PKPavlo G. Kravchun
Pavlo G. Kravchun
VBVolodymyr D. Babadzhan
Volodymyr D. Babadzhan
OYOleksandra S. Yermak
Oleksandra S. Yermak
The aim. To evaluate the presence and nature of changes in the morpho-functional state of the myocardium in patients with coronary heart disease (CHD) with concomitant type 2 diabetes mellitus (T2DM) and obesity, depending on the functional class (FC) of chronic heart failure (CHF) and the relationship with the concentration of galectin-3 in blood serum. Materials and methods. The study involved 75 patients with CHD with concomitant metabolic diseases such as T2DM and obesity, who were treated in the cardiology department of the State Clinical Hospital No. 27. Patients were divided into groups according to the FC of CHF. Group 1 included 30 patients with CHF FC II, group 2 – 24 patients with CHF FC III, group 3 – 21 patients with CHF FC IV. Results. In patients with СHD and metabolic disorders with CHF FC III, the levels of end-systolic dimension (ESD) and end-diastolic dimension (EDD) were higher by 16.3 % and 17.9 %, respectively, compared with FC II, end-systolic volume (ESV) and end-diastolic volume (EDV) also increased significantly in patients of this cohort with FC III compared with CHF FC II by 35.8 % and 16.5 %, respectively. Significantly increased ESV, EDV by 42.9 % and 37.8 %, respectively, as well as the size of the left atrium by 14.3 % in patients of the study group who had CHF FC IV compared with FC III. The ejection fraction (EF) index decreased in patients of this cohort with CHF FC IV by 14.4 % compared with FC III. The size of the right ventricle was larger by 10.8 % in CHF FC IV than in FC III in patients with CHD on the background of comorbid metabolic pathology. Indicators of the thickness of the LV posterior wall, LV relative wall thickness and intraventricular septum were lower in patients with FC IV compared with FC II, left ventricle mass (LVM) and left ventricle mass index (LVMI) increased by 32 % and 33 %, respectively. Сomparing the levels of Ea/Es in patients with CHF FC II and IV in СHD with concomitant T2DM and obesity, a significant increase in this indicator was found in FC IV (p<0.05). The level of galectin-3 in patients with CHF FC III and IV of ischemic origin against the background of concomitant metabolic disorders was higher than in patients with FC II. Сomparing the concentration of galectin-3 in patients with CHF FC III and IV in patients with CHD with comorbid metabolic pathology, significantly higher levels were found in FC IV (p<0.05). The study of the relationship between the fibrosis factor galectin-3 and cardiohemodynamic parameters revealed probable links, namely direct links between galectinemia and ESV (r=0.52; p<0.05), EDV (r=0.58; p<0.05), Еа/Es (r=0.51; p<0.05). Conclusions. The growth of the functional class of chronic heart failure is accompanied by dilatation of the left cavities of the heart, a decrease in the inotropic function of the left ventricle, an increase in myocardial-arterial stiffness, and an increase in the levels of the galectin-3 fibrosis factor in the studied patients.

1 February 2024 in Immunology and Allergology: Science and Practice
Verified
Journal Article
Open access
PDF file
VBVolodymyr Babadzhan
Volodymyr Babadzhan
YBYelyzaveta Byrka
Yelyzaveta Byrka
AKAnastasiia Kliepova
Anastasiia Kliepova
ASAlbina Solovei
Albina Solovei
AYAnastasiia Yaresko
Anastasiia Yaresko
The aim. To study and summarize modern immunological methods of laboratory diagnosis of the causes of infertility. Materials and methods. An analytical review and analysis of the scientific literature in recent years, covering the study of immunological causes of infertility and, accordingly, the use of immunological methods of diagnosis and treatment of infertility. Results and discussion. Infertility treatment is an urgent medical problem because, according to the WHO, every sixth person faces this problem during their lifetime. Immunological aspects play an important role in infertility and account for 5% of infertility among men and women. In cases where the cause of infertility cannot be explained by the presence of specific organic signs in a couple, the identification of immunological mechanisms of infertility becomes more crucial. The immunological causes of infertility are still underestimated, as the mother’s immune system plays a major role in the successful implantation of the embryo and the carrying of a pregnancy. The relevant areas of immunological research are HLA typing to determine the immunological «compatibility» of couples, the study of the role of antisperm antibodies (ASA) in the development of infertility, and the use of exosomes as biomarkers of reproductive system diseases that may be the cause of infertility. In accordance with the material reviewed, we have identified the main areas of research into the causes, diagnosis, and treatment of infertility, which require further detailed study for the successful overcoming of infertility in the future. Conclusion. We have reviewed the articles that included materials on the study of immunological methods of infertility research and identified three currently relevant methods for identifying the causes and diagnosis of this disease, which continue to require thorough study to solve the problems of infertility. Carriage of the HLA-DQA1*5 allele can be used as a marker of the degree of HLA-DQA1 compatibility of a couple, as well as the use of some exosome markers, such as endometriosis-specific exosome characteristics such as miR-214-3p, EVLGMNP1, AFAP1-AS1. There is also no doubt that there is a high correlation between elevated levels of ASA and female infertility, so special attention should be paid to ASA in the diagnosis of male infertility.

22 March 2024 in Asthma and allergy
Verified
Journal Article
Open access
ВБВ. Д. Бабаджан
В. Д. Бабаджан
СЗС. В. Зайков
С. В. Зайков
МЛМ. А. Ликова
М. А. Ликова
Резюме.Метою цієї частини огляду літератури є характеристика епідеміології, визначення фенотипів та ендотипів анафілаксії, патогенетичних механізмів її розвитку, систематизація на їх основі клінічних проявів та ступенів тяжкості даного стану, оцінка можливих біомаркерів анафілаксії для їх більш широкого впровадження в клінічну практику.Анафілаксія є найважчою з алергічних реакцій, що наражає пацієнтів на високий ризик втрати життя і вимагає швидкого розпізнавання танегайного лікування. Однак, оскільки її симптоми імітують прояви інших захворювань, таких як астма та кропив’янка, то діагностикаанафілаксії часто недостатньо результативна через дуже рідке визначення рівня триптази, тому лікування пацієнтів запізнюється, епінефрин (адреналін) використовується пізно. Основні причини розвитку анафілаксії вивчені недостатньо, а смерть внаслідок її виникненнячасто важко дослідити через неправильну діагностику даного стану.

24 June 2024 in Asthma and allergy
Verified
Journal Article
Open access
ВБВ. Д. Бабаджан
В. Д. Бабаджан
СЗС. В. Зайков
С. В. Зайков
МЛМ. А. Ликова
М. А. Ликова
Резюме. Мета огляду – систематизація і розгляд біомаркерів анафілаксії для їх широкого клінічного застосування, що зробить діагностику цього захворювання ранньою та точною, а лікування більш ефективним. Нова класифікація анафілаксії, заснована на точній медицині з використанням фенотипів, ендотипів і біомаркерів, розширила класифікацію Ф. Гелла і Р. Кумбса, що дозволило краще ідентифікувати та лікувати анафілаксію. Шкірні тести, визначення специфічних IgE, алергокомпонентна діагностика є безпечними інструментами для виявлення сенсибілізації до численних алергенів, особливо у пацієнтів з високим ризиком, наприклад, у пацієнтів з раком, муковісцидозом і мастоцитозом. Інші біомаркери, такі як тест активації базофілів, визначення рівня триптази є корисними діагностичними інструментами, які увійдуть у повсякденну алергологічну практику у недалекому майбутньому. Рівень триптази бажано визначати з 30 хвилин до 3 годин після початку реакції, триптаза є на даний момент найкращим біомаркером, який підтверджує діагноз анафілаксії. Більше 30 % пацієнтів з ідіопатичною або неспровокованою анафілактією можуть мати основну патологію – захворювання клональних опасистих клітин. Визначення рівня триптази у таких хворих може допомогти ідентифікувати пацієнтів із клональними захворюваннями опасистих клітин.